Therapeutic Targets Database
BIDD Pharmainformatics Databases
 
   
 

 

TTD Drug ID: DAP000629

Drug Information
NameTerconazole    
SynonymsAC1L1KA5; Prestwick_812; 85058-79-3; AB00513849; Tetrazol 3; HMS1569D11; Fungistat; 1-[4-[[(2R,4S)-2-(2,4-dichlorophenyl)-2-(1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy]phenyl]-4-propan-2-ylpiperazine; terconazole; CID50001; UNII-0KJ2VE664U; Prestwick3_000495; CID5404; Terazol Cream & Suppositories; Terazol; BPBio1_000429; 1-[4-[[(4S)-2-(2,4-dichlorophenyl)-2-(1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy]phenyl]-4-propan-2-ylpiperazine; BIDD:GT0705; D00888; 1-(4-((2-(2,4-dichlorophenyl)-2-(1H-1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl)methoxy)phenyl)-4-(1-methylethyl)piperazine; CAS-67915-31-5; Terazol 7 3; Terazol 3; CHEMBL1306; CID9936883; Zazole; Terconazole (USAN/INN); Terazol 7 & 3; NSC 331942; Piperazine, 1-(4-(((2R,4S)-2-(2,4-dichlorophenyl)-2-(1H-1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl)methoxy)phenyl)-4-(1-methylethyl)-, rel-; NCGC00179575-01; SMR001565413; SPBio_002310; Tercospor; R 42470; AC1L1895; Gyno-Terazol; AC1LA3NV; AR-1L5963; Terazol 3 (TN); Prestwick1_000495; MLS002153844; Prestwick2_000495; Terazol 7; Piperazine, 1-(4-((2-(2,4-dichlorophenyl)-2-(1H-1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl)methoxy)phenyl)-4-(1-methylethyl)-, cis-; AC1Q3MYQ; NSC331942; Prestwick0_000495; Terconazolum; BSPBio_000389; C26H31Cl2N5O3; AR-1I2364; 1-[4-[[2-(2,4-dichlorophenyl)-2-(1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy]phenyl]-4-propan-2-ylpiperazine; Triaconazole; C08080; nchembio.154-comp19; EINECS 267-751-6; Terconazolum [INN-Latin]; LS-176634; 1-[4-[[(2S,4R)-2-(2,4-dichlorophenyl)-2-(1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy]phenyl]-4-propan-2-ylpiperazine; Tetrazol 7; 67915-31-5; DB00251; AC1L9B2M; Terconazol; NCGC00016912-01; Terconazole [USAN:INN:BAN]; MLS002701820; R-42470; BRD-K86204871-001-02-2; AC1Q3N0B; Terconazol [INN-Spanish]; CID480953; Piperazine, 1-[4-[[2-(2,4-dichlorophenyl)-2-(1H-1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy]phenyl]-4-(1-methylethyl)-, rel-(2R,4S); CID441383; cis-1-(p-((2-(2,4-Dichlorophenyl)-2-(1H-1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl)methoxy)phenyl)-4-isopropylpiperazine; SMR001233206; R 42,470    
IndicationFungal infectionsApproved    [1]
Structure

Click to save drug structure in 3D MOL format

Click to save drug structure in 2D MOL format
   
Therapeutic ClassAntifungal Agents    
CAS NumberCAS 67915-31-5
FormularC26H31Cl2N5O3    
PubChem Compound IDCID 9936883.    
PubChem Substance IDSID 14910040.    
SuperDrug ATC IDG01AG02;    
SuperDrug CAS ID067915315;    
TargetCytochrome P450 51Inhibitor[2]
Ref 1FDA Approved Drug Products from FDA Official Website. 2009. Application Number: (NDA) 021735 To Reference
Ref 2Mode of action of anti-Candida drugs: focus on terconazole and other ergosterol biosynthesis inhibitors. Am J Obstet Gynecol. 1991 Oct;165(4 Pt 2):1193-9. To Reference



 

Welcome to sign our Guestbook.

If you find any error in data or bug in web service, please kindly report it to Dr. Zhu.


Dr. Chen Yuzong
Deputy Director of Center for Computational Science and Engineering
Professor in Department of Pharmacy
National University of Singapore, Singapore


All rights reserved.

 
   
           
 
Computer-aided Drug Design
About BIDD | Databases | Software | Teaching | Research |  Links

Department of Computational Science | National University of Singapore | Blk S17, 3 Science Drive 2, Singapore 117543